Abbott and Nihon Kohden Corporation have entered into an agreement for the commercialization of automated haematology diagnostic instruments for use in hospital laboratories and physician offices.
Haematology instruments are used to perform complete blood counts (CBCs), a test routinely ordered by doctors to assess a patient's overall health and to screen for a variety of disorders such as anaemia and infection.
Under terms of the agreement, two 5-part differential haematology instruments, which are designed to offer red and white blood cell analysis, will be manufactured by Nihon Kohden and distributed by Abbott under the CELL-DYN Pearl brand name. Abbott obtains exclusive distribution rights for the two instruments in the United States and Canada and non-exclusive distribution rights for the instruments in other countries with the exception of China and Japan, release from Abbott said.
"A key part of the agreement was the commitment both companies have to improving patient care through scientific advances in medical technology. Nihon Kohden's innovative technology in blood analysis complements Abbott's capabilities and proprietary technology," said Harold Flynn, divisional vice president and general manager, Abbott Haematology.
Nihon Kohden is Japan's leading manufacturer, developer and distributor of patient monitors, EEGs, EP/EMGs, ECGs, defibrillators, haematology analyzers and other medical electronic equipment with subsidiaries in the United States, Europe and Asia.